Radioresistance in rectal cancer: can nanoparticles turn the tide?

Area of Science:

• Oncology
• Gastroenterology
• Nanomedicine

Background:

• Rectal cancer represents over 35% of colorectal cancers globally, with distinct molecular and anatomical characteristics compared to colon cancer.
• Neoadjuvant chemoradiotherapy is crucial for locally advanced rectal cancer, but radioresistance frequently leads to poor outcomes.
• Understanding these differences is key to developing more effective treatment strategies.

Purpose of the Study:

• To elucidate the molecular distinctions between rectal and colon tumors.
• To explore the mechanisms underlying radioresistance in rectal cancer.
• To review promising nanomedicines for enhancing neoadjuvant therapy response.

Main Methods:

• Literature review of molecular differences between rectal and colon cancers.
• Analysis of studies investigating rectal cancer radioresistance.
• Survey of nanomedicine applications in rectal cancer treatment.

Main Results:

• Rectal and colon cancers exhibit significant molecular variations influencing treatment approaches.
• Radioresistance in rectal cancer is a complex phenomenon linked to poor prognosis.
• Various nanomedicines demonstrate potential for improving radiotherapy efficacy and drug delivery.

Conclusions:

• Targeting molecular differences and overcoming radioresistance are critical for advancing rectal cancer therapy.
• Nanomedicine offers a viable strategy to enhance neoadjuvant chemoradiotherapy effectiveness.
• Further research into targeted nanomedicine delivery can improve patient outcomes.